Home Insights Eyes on Health Economics: A Deep Dive by Commercial Eyes

Eyes on Health Economics: A Deep Dive by Commercial Eyes

An Introduction to Economic Evaluation for Pharma Professionals

Join us on Zoom for a captivating 1.5-hour live training session with Jo Atkins, Head of Access, Research & Intelligence and Scott Richards-Jones, a former PBAC evaluator as we unravel the intricacies of economic evaluation tools and theories in the context of Australian health technology assessment (HTA) submissions. This informative session is the first in the Eyes on Webinar Series by Commercial Eyes and is perfect for industry newcomers stepping into market access.

Discussion points

  • Delve deep into the economic theories underpinning health technology evaluations.
  • Grasp the economic frameworks pivotal for Australian health technology assessment (HTA) submissions.

Key takeaways

  • Establishing the PICO (Population/Intervention/Comparator/Outcomes) framework is the first step. Once set and backed with clinical evidence or to justify the clinical claim, the spotlight shifts to the economic evidence.
  • A convincing economic analysis means highlighting the value-for-money proposition of the intervention, without overlooking inherent uncertainties.
  • Claims asserting clinical superiority must be bolstered by a top-tier economic evaluation.

Location: Zoom Online

Date: Wednesday, 8th November 2023

Time: 10:00AM – 11:30AM AEDT

Registration cost: $100

Jo Atkins


Jo Atkins leads the Access, Research and Intelligence (ARI) team at Commercial Eyes. Jo is a registered pharmacist with post graduate qualifications in marketing, health economics and competitive intelligence. With over 25 years industry experience, including 18 years as a consultant, Jo has significant experience and a passion for product commercialisation and market access.

Scott Richards-Jones


Scott Richards-Jones has a post graduate qualification in Health Economics and an undergraduate qualification in Biological Sciences. Scott began working in the HTA industry as an evaluator for the PBAC, conducting numerous evaluations of HTA submissions for pharmaceutical reimbursement. In that role, Scott developed a technical skillset for dissecting HTA submissions as well as an extensive understanding of the PBAC decision-making framework.

For more information, please contact us at [email protected]